These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 12230262)

  • 1. Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
    Pool JL; Kirby RS
    Int Urol Nephrol; 2001; 33(3):407-12. PubMed ID: 12230262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History and nomenclature of alpha1-adrenoceptors.
    Langer SZ
    Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. alpha1- and alpha2-adrenoceptors in BPH.
    Takeda M; Hatano A; Arai K; Obara K; Tsutsui T; Takahashi K
    Eur Urol; 1999; 36 Suppl 1():31-4; discussion 65. PubMed ID: 10393470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenoceptor pharmacology: urogenital applications.
    Ruffolo RR; Hieble JP
    Eur Urol; 1999; 36 Suppl 1():17-22. PubMed ID: 10393468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Hayase M; Hayashi Y; Shinoura H; Tsujimoto G; Kohri K
    J Urol; 2008 Mar; 179(3):1040-6. PubMed ID: 18206918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
    Wilde MI; Fitton A; McTavish D
    Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
    Beduschi MC; Beduschi R; Oesterling JE
    Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors.
    Proudman RGW; Pupo AS; Baker JG
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00602. PubMed ID: 32608144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomenclature and state of the art on alpha1-adrenoceptors.
    Langer SZ
    Eur Urol; 1998; 33 Suppl 2():2-6. PubMed ID: 9556189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Elhilali MM
    Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
    J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
    Chapple CR
    Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].
    Muramatsu I; Suzuki F; Tanaka T; Yamamoto H; Morishima S
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():187-98. PubMed ID: 16518082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha1-Adrenoceptor subtype selectivity and lower urinary tract symptoms.
    Schwinn DA; Price DT; Narayan P
    Mayo Clin Proc; 2004 Nov; 79(11):1423-34. PubMed ID: 15544022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Int J Clin Pract; 1998 Sep; 52(6):402-7. PubMed ID: 9894377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of alpha1-adrenoceptor antagonists in benign prostatic hyperplasia based on the receptor occupancy theory.
    Ito K; Ohtani H; Sawada Y
    Br J Clin Pharmacol; 2007 Apr; 63(4):394-403. PubMed ID: 17052252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.
    Michel MC; Grübbel B; Taguchi K; Verfürth F; Otto T; Kröpfl D
    J Auton Pharmacol; 1996 Feb; 16(1):21-8. PubMed ID: 8736427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concept of uroselectivity.
    Andersson KE
    Eur Urol; 1998; 33 Suppl 2():7-11. PubMed ID: 9556190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.